| Popis: |
Background: Colorectal cancer is the third most common cancer worldwide, with colon cancer representing 66.7% of cases. Treatment consists of surgical resection and chemotherapy; however, this is less effective at the later stages of the disease. Gene targeted therapies represent a promising treatment option and, where available, show a significant improvement in overall patient survival. The present study investigated the genetic alteration occurring in colon cancer and used this to produce a predictive model for patient overall survival. Methods: The data was obtained from the cBioPortal database (cbioportal.org) and was used to analyse genetic alteration in 1272 colon cancer patients. Kaplan-Meyer analysis was used to evaluate the effect of specific gene alteration and patient information on overall survival. Results: Genetic alteration to either APC, PTPRT, SRC, and TP53 were associated with improved patient overall survival compared to wild-type. Conversely, alteration to BRAF, CSMD1, FBXW7, MACROD2, RBFOX1, SYNE1, TTN, and WWOX were associated with worse overall survival. Patient data indicated that BMI, sex, TMB, and stage at diagnosis had no significant effect in this population, whilst an age greater than 60 years and right sided cancer was associated with a worse overall survival irrespective of genetic alteration. These factors were used to produce a predictive model for colon cancer overall survival. Conclusions: This study provides a partially predictive model for clinical research to estimate overall survival in colon cancer patients. Understanding the precise clinical significance of tumour genetics will result in a more tailored approach to the treatment of the disease. |
